Thrivent Financial for Lutherans Sells 33,482 Shares of Repligen Co. (NASDAQ:RGEN)

Thrivent Financial for Lutherans lessened its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 5.2% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 605,120 shares of the biotechnology company’s stock after selling 33,482 shares during the period. Thrivent Financial for Lutherans owned 1.08% of Repligen worth $87,101,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. UMB Bank n.a. boosted its holdings in Repligen by 49.1% in the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 110 shares during the last quarter. First Turn Management LLC bought a new position in Repligen in the third quarter valued at about $13,202,000. Oppenheimer & Co. Inc. bought a new position in Repligen in the fourth quarter valued at about $216,000. Worldquant Millennium Advisors LLC boosted its holdings in Repligen by 11.9% in the third quarter. Worldquant Millennium Advisors LLC now owns 50,276 shares of the biotechnology company’s stock valued at $7,482,000 after acquiring an additional 5,337 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Repligen by 1.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 363,379 shares of the biotechnology company’s stock worth $54,078,000 after buying an additional 5,478 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on RGEN shares. HC Wainwright restated a “buy” rating and set a $180.00 target price on shares of Repligen in a report on Friday, February 21st. Canaccord Genuity Group raised their target price on Repligen from $165.00 to $170.00 and gave the stock a “hold” rating in a report on Friday, February 21st. StockNews.com cut Repligen from a “hold” rating to a “sell” rating in a report on Friday, February 21st. Canaccord Genuity Group started coverage on Repligen in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price on the stock. Finally, TD Cowen started coverage on Repligen in a report on Monday, February 10th. They set a “buy” rating and a $200.00 target price on the stock. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $178.64.

Insiders Place Their Bets

In related news, Director Margaret Pax purchased 250 shares of the stock in a transaction on Monday, March 17th. The shares were purchased at an average price of $150.69 per share, with a total value of $37,672.50. Following the transaction, the director now directly owns 1,043 shares of the company’s stock, valued at $157,169.67. This trade represents a 31.53 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 1.20% of the company’s stock.

Repligen Trading Down 5.5 %

NASDAQ:RGEN opened at $144.34 on Wednesday. Repligen Co. has a fifty-two week low of $113.50 and a fifty-two week high of $200.23. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The stock has a market capitalization of $8.09 billion, a PE ratio of -283.02, a price-to-earnings-growth ratio of 4.54 and a beta of 0.95. The business’s 50-day simple moving average is $156.98 and its 200-day simple moving average is $148.49.

Repligen (NASDAQ:RGEN) last announced its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.03. The business had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. Sell-side analysts expect that Repligen Co. will post 1.72 earnings per share for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.